JP2020534354A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534354A5
JP2020534354A5 JP2020536930A JP2020536930A JP2020534354A5 JP 2020534354 A5 JP2020534354 A5 JP 2020534354A5 JP 2020536930 A JP2020536930 A JP 2020536930A JP 2020536930 A JP2020536930 A JP 2020536930A JP 2020534354 A5 JP2020534354 A5 JP 2020534354A5
Authority
JP
Japan
Prior art keywords
cdk19
tnbc
treatment
seq
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020536930A
Other languages
English (en)
Japanese (ja)
Other versions
JP7392954B2 (ja
JP2020534354A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/051489 external-priority patent/WO2019055977A1/en
Publication of JP2020534354A publication Critical patent/JP2020534354A/ja
Publication of JP2020534354A5 publication Critical patent/JP2020534354A5/ja
Application granted granted Critical
Publication of JP7392954B2 publication Critical patent/JP7392954B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020536930A 2017-09-18 2018-09-18 トリプルネガティブ乳癌の治療方法 Active JP7392954B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560140P 2017-09-18 2017-09-18
US62/560,140 2017-09-18
PCT/US2018/051489 WO2019055977A1 (en) 2017-09-18 2018-09-18 METHODS OF TREATING NEGATIVE TRIPLE BREAST CANCER

Publications (3)

Publication Number Publication Date
JP2020534354A JP2020534354A (ja) 2020-11-26
JP2020534354A5 true JP2020534354A5 (https=) 2021-10-28
JP7392954B2 JP7392954B2 (ja) 2023-12-06

Family

ID=65723126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020536930A Active JP7392954B2 (ja) 2017-09-18 2018-09-18 トリプルネガティブ乳癌の治療方法

Country Status (6)

Country Link
US (2) US11471477B2 (https=)
EP (1) EP3684420A4 (https=)
JP (1) JP7392954B2 (https=)
CN (1) CN111278469A (https=)
AU (1) AU2018333072B2 (https=)
WO (1) WO2019055977A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023044041A1 (en) * 2021-09-16 2023-03-23 University Of South Carolina Cdk8/19 inhibitors for preventing drug resistance
CN114908168A (zh) * 2022-05-04 2022-08-16 重庆大学附属肿瘤医院 一种mon1a表达水平检测试剂在制备卵巢癌干性诊断试剂中的应用
CN114854755B (zh) * 2022-05-30 2023-05-23 陕西师范大学 一种抑制vstm2l表达的慢病毒载体及其应用
CN114832110B (zh) * 2022-06-21 2023-04-28 中山大学孙逸仙纪念医院 长链非编码rna crcal-3抑制剂在制备治疗放疗抵抗乳腺癌的产品中的用途
WO2024100556A1 (en) * 2022-11-07 2024-05-16 Cbsbioscience Co., Ltd. Methods and compositions for predicting and treating triple negative breast cancer
EP4620979A1 (en) * 2022-11-14 2025-09-24 Cognano, Inc. Antibody and method for producing antibody
WO2025020931A1 (en) * 2023-07-21 2025-01-30 The Chinese University Of Hong Kong Cdk20 in cancer diagnosis and therapy
CN116773815B (zh) * 2023-08-14 2023-11-10 四川省医学科学院·四川省人民医院 Slc2a6作为治疗靶点和筛查靶点的用途及乳腺癌筛查试剂盒
CN117144008B (zh) * 2023-08-31 2024-03-08 武汉科技大学 三阴性乳腺癌生物标志物及其应用
CN118001402B (zh) * 2024-01-10 2025-09-05 中山大学 Pacsin2在促进sting信号通路激活中的应用
CN119264251B (zh) * 2024-12-09 2025-03-14 上海交通大学医学院附属仁济医院 一种cbln1单克隆抗体和应用
CN120309727B (zh) * 2025-06-13 2025-08-15 昆明医科大学 一种靶向人igfl1的单域抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US20080293142A1 (en) 2007-04-19 2008-11-27 The Board Of Regents For Oklahoma State University Multiple shRNA Expression Vectors and Methods of Construction
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
AU2011330733A1 (en) * 2010-11-19 2013-06-06 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a CDK inhibitor
EA027531B1 (ru) * 2011-09-13 2017-08-31 Игорь Ронинсон ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB
EP3730618A1 (en) 2011-11-18 2020-10-28 Alnylam Pharmaceuticals, Inc. Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
KR20150023223A (ko) 2012-02-02 2015-03-05 세넥스 바이오테크놀러지 인코포레이티드 Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도
KR20160014568A (ko) 2012-11-01 2016-02-11 유니버시티 오브 싸우스 캐롤라이나 전립선암을 치료하는 방법
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US20170115308A1 (en) 2014-11-14 2017-04-27 Senex Biotechnology, Inc. Assay to measure efficacy of cdk8/19 inhibitors
AR102298A1 (es) * 2015-01-19 2017-02-15 Takeda Pharmaceuticals Co Compuesto heterocíclico fusionado
TW201714883A (zh) * 2015-10-16 2017-05-01 武田藥品工業股份有限公司 雜環化合物
CN114921468A (zh) 2017-01-30 2022-08-19 国立大学法人京都大学 新型化合物以及调节性t细胞的制造方法

Similar Documents

Publication Publication Date Title
JP2020534354A5 (https=)
Liu et al. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway
Yang et al. MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway
Garza Treviño et al. Effects of pericytes and colon cancer stem cells in the tumor microenvironment
Li et al. Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma
Avan et al. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer
Zhang et al. CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer
Hwang et al. Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1
Zhao et al. MiR-874 inhibits cell growth and induces apoptosis by targeting STAT3 in human colorectal cancer cells.
Yang et al. Hepatitis B virus X protein enhances hepatocarcinogenesis by depressing the targeting of NUSAP1 mRNA by miR-18b
Pan et al. MiR-195-5p inhibits the cell migration and invasion of cervical carcinoma through suppressing ARL2
Gao et al. miR-200a inhibits tumor proliferation by targeting AP-2γ in neuroblastoma cells
Pai et al. Prospects of miRNA-based therapy for pancreatic cancer
Hong et al. The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients
Liu et al. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
Shi et al. SET8 expression is associated with overall survival in gastric cancer
Nie et al. GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma
Wu et al. KAP1 inhibits the Raf‐MEK‐ERK pathway to promote tumorigenesis in A549 lung cancer cells
Zhang et al. MiR-886-5p inhibition inhibits growth and induces apoptosis of MCF7 cells
Zaczek et al. Mechanisms of senescence in cancer: positive and negative aspects of cancer cells senescence
Chen et al. The roles of miRNA-143 in colon cancer and therapeutic implications
Czerniak et al. Biomarkers could facilitate prediction of worse clinical outcome of cancer with special insight to cervical cancer
Choi et al. Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen-independent prostate cancer cells
WO2024186883A2 (en) Compositions and methods for the treatment of human papillomavirus-driven cancers
WO2005104785A3 (en) Methods and compositions for specifically targeting human hepatocellular carcinoma cells